GSK plc

GSK

GB00BN7SWP63

Pharmaceuticals

Market Closed - London S.E. Other stock markets 11:35:09 2024-09-20 am EDT			5-day change	1st Jan Change
1,536.00 ^GBX	-2.45%		-5.97%	+5.92%

Sep. 20	Iconovo Gets US FDA's Positive Feedback for Generic Inhaler Product	MT
Sep. 19	Alector Reports Baseline Characteristics for Phase 3 Latozinemab Trial for Frontotemporal Dementia	MT

GSK : JP Morgan reiterates its Sell rating

August 02, 2024 at 04:38 am EDT

JP Morgan analyst James Gordon reiterate his Sell rating on the stock. The target price is lowered from GBX 1660 to GBX 1550.

Latest news about GSK plc

Iconovo Gets US FDA's Positive Feedback for Generic Inhaler Product	Sep. 20	MT
Alector Reports Baseline Characteristics for Phase 3 Latozinemab Trial for Frontotemporal Dementia	Sep. 19	MT
GSK plc Presents at Bank of America Global Healthcare Conference 2024, Sep-19-2024 08:05 AM	Sep. 19
European Equities Close Lower in Wednesday Trading; EU, Euro Area Inflation Declines in August	Sep. 18	MT
GSK Settles Two California Lawsuits Related to Zantac	Sep. 18	MT
GSK: two Zantac-related claims settled out of court	Sep. 18	CF
Britain's GSK Reaches Settlements for Two US Lawsuits	Sep. 18	MT
GSK settles two California lawsuits related to heartburn drug Zantac	Sep. 18	RE
GSK reaches further two settlements regarding Zantac	Sep. 18	AN
GSK : Jefferies reaffirms its Buy rating	Sep. 18	ZD
GSK Says Trial Evaluating Co-Administration of AREXVY, SHINGRIX Shows Non-Inferior Immune Response	Sep. 18	MT
GSK Sees Positive Results in Trial of Combination RSV, Shingles Vaccine	Sep. 18	DJ
GSK plc Announces Positive Topline Data on Co-Administration of AREXVY and SHINGRIX	Sep. 18	CI
IDEAYA Biosciences, Inc. Appoints Douglas B. Snyder as Senior Vice President, General Counsel	Sep. 18	CI
European Equities Traded in the US as American Depositary Receipts Edge Lower in Tuesday Trading	Sep. 17	MT
GSK: Japan agrees to review Blenrep application	Sep. 17	CF
GSK : JP Morgan remains a Sell rating	Sep. 17	ZD
GSK says Blenrep combinations accepted for review in Japan	Sep. 17	AN
GSK's Blood Cancer Treatment Application Accepted for Review in Japan	Sep. 17	MT
GSK PLC : Despite transitioning towards speciality pharma, GSK is trading at OTC prices	Sep. 16
ITeos Therapeutics Shares Rise on Positive Data From Lung Cancer Study	Sep. 16	DJ
GSK : Goldman Sachs gives a Neutral rating	Sep. 16	ZD
Moderna's Faces 'Material Headwinds' on RSV, COVID, RBC Says	Sep. 13	MT
GSK Bets on Blood-Cancer Drug Comeback Amid Oncology Push	Sep. 13	DJ
European Equities Close Higher on Friday; HSBC Mulls Potential Sale of South African Unit	Sep. 13	MT

GSK plc is a global biopharma company. The Companyâs segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. Its product areas include vaccines, specialty medicines, and general medicine. It is also focused on addressing the unmet treatment needs of patients with respiratory and inflammatory conditions. Its vaccine portfolio includes over 20 vaccines that help to protect people from a range of diseases and infections, including meningitis, shingles and flu, among others. Its specialty medicines are also engaged in developing medicines for respiratory disease and HIV. Its general medicines include inhaled medicines for asthma and chronic obstructive pulmonary disease, antibiotics, and medicines for skin diseases. It is advancing oligonucleotide therapeutics in chronic hepatitis B and steatotic liver disease as well as other therapeutic areas beyond liver disease.

Employees

70,212

Sector

Pharmaceuticals

Calendar

2024-10-30 - Q3 2024 Earnings Release

More about the company